Oct 20, 2026 - 7 AI models call the biggest movers in the morning session. 6 models finished positive

Asked Oct 20, 10:07 AM EDT (morning session). Claude Sonnet 5.5, GPT-6, Muse Spark 1.1, Perplexity, Gemini 3 Pro, DeepSeek and Grok answered the same standard prompt independently. Window: from Oct 20, 10:07 AM EDT to Oct 21, 10:07 AM EDT, the same time one session later. Benchmark: SPY.

Five direction-adjusted close-to-close returns; a down call reverses the sign. The score is the mean signed return, without subtracting the benchmark. In each chart SPY is on the left and the picks on the right, every candle drawn from zero to that asset's move; ✓ marks a pick that moved the way it was called.

Model	Correct	Hit rate	Return	SPY	Directional return
Claude Sonnet 5.5	0/5	0.00%	-3.67%	0.13%	-3.67%
GPT-6	4/5	80.00%	3.01%	0.13%	3.01%
Muse Spark 1.1	3/5	60.00%	2.51%	0.13%	2.51%
Perplexity	4/5	80.00%	2.81%	0.13%	2.81%
Gemini 3 Pro	4/5	80.00%	1.35%	0.13%	1.35%
DeepSeek	2/5	40.00%	0.25%	0.13%	0.25%
Grok	4/5	80.00%	1.42%	0.13%	1.42%

Claude Sonnet 5.5

View full picks and reasoning

On Oct 19 (source session) risk appetite returned: semiconductors rebounded after a nine-session losing streak, and Amazon, Datadog and Intel rose on analyst actions. Extreme single-name moves were mostly catalyst-driven (Disc Medicine Phase 3 data, Cleveland-Cliffs earnings) or drift/sentiment-driven (Sea, QXO, AXT). This is a mixed book of two fade-the-spike calls with a financing overhang or post-earnings giveback (IRON, CLF), one fade of a speculative bounce in a downtrend (AXTI) and two oversold-bounce calls (SE, QXO). Confidence is modest throughout because intraday quotes were taken around 09:16-10:16 EDT from a delayed/aggregated page and the exact price at the 14:07:33Z window start could not be verified.

1. CLF down — confidence 52%. Source session Oct 19: CLF +16.34% to close 14.10 on Q3 results (adjusted EPS 28c vs 24c consensus, revenue 5.6B vs 5.72B consensus, adjusted EBITDA 612M, Q4 EBITDA guide ~715M, FY27 EBITDA guide above 4B). Hypothesis: reversal, direction down. Catalyst assessment: facts are the EPS beat, the strong 2027 outlook and tariff-supported pricing (Barron's, Invezz, TheFly via stockanalysis.com), which changes earnings expectations and is substantive; inference is that much of the re-rating is already priced after a +16% day. Revenue missed, and the 2027 guide depends on steel-price assumptions. Latest quote: latest_price 13.15 USD, quote_time 2026-10-20T10:16:00-04:00 (2026-10-20T14:16:00Z), source https://stockanalysis.com/stocks/clf/, delayed/near-real-time regular-session quote. Another fetch of the history page showed 13.45 labelled 10:25 AM EDT, so timestamps are inconsistent and freshness is uncertain. (1) Pre-event price: 12.12 on 2026-10-16 close (https://stockanalysis.com/stocks/clf/history/). (2) Observed event-to-quote move: about +8.5% (13.15/12.12-1). The Oct 19 close was 14.10 and the stock is already -6.77% on Oct 20. (3) Expected after the quote: partial further gap-fill toward the 12.12-12.7 area as the 88.2M-share blowoff (about 4x the 21.4M 20-day average) digests; consensus price target is 12.60. PARTIAL SESSION as of 10:16 EDT: open 13.68, high_so_far 13.72, low_so_far 12.63, cumulative_volume 11,300,882; relative intraday volume cannot be established (no same-time baseline). Price action: Oct 19 opened 14.20, ranged 12.94-14.58 and closed 14.10, below the high, after a 9.4% 5-day gain and a break above the 20-day high of 14.58 was not held at the close. Strongest counter-evidence: Wells Fargo raised its target to 17 and Morgan Stanley to 14 on Oct 20, and 2027 guidance is far above the ~2.5B EBITDA the Street expected (Invezz), so post-earnings drift could resume. Invalidation: a sustained move back above the Oct 19 high of 14.58 on strong volume, or evidence of improved steel pricing/guidance beyond what was reported. Market cap 7.50B at 13.15 quote (stockanalysis.com); 20-day average dollar volume about 268.9M computed from daily closes and volumes.
   Return: 4.80%; alpha: -4.93%.
2. AXTI down — confidence 50%. Source session Oct 19: AXTI +10.34% to close 56.79, a bounce after -11.12% on Oct 16. Hypothesis: reversal, direction down. Catalyst assessment: no company-specific news was found for Oct 19 (TheFly only reports price moves); the next scheduled event is Q3 earnings on Oct 29 (Business Wire). The bounce looks sentiment/semiconductor-rebound driven (SMH rose after nine losing days, per CNBC) rather than a change in business expectations; that is inference. Background facts: Q2 2026 results were a record and a Lumentum supply agreement was signed (stockanalysis.com summaries). Latest quote: latest_price 55.25 USD, quote_time 2026-10-20T10:16:00-04:00 (2026-10-20T14:16:00Z), source https://stockanalysis.com/stocks/axti/, delayed/near-real-time regular-session quote (previous close 56.79, -2.71%). No verified pre-event price, so event-to-quote move is null. Expected move after the quote: continued fade within a downtrend (price down from 88.36 high on Oct 6 to 50.57 low on Oct 16; 10 declines in the last 13 sessions). PARTIAL SESSION as of 10:16 EDT: open 54.59, day range 51.51-55.32, cumulative_volume 3,056,165; relative intraday volume cannot be established. Price action: Oct 19 closed 56.79 in the upper half of a 54.66-59.43 range, still well below the 20-day high; the 20-day range (50.57-88.36) shows a breakdown with a retest. Counter-evidence: the stock was +10% on 13.55M shares (1.6x the 8.5M average), analysts' average target is 91.60, and extremely high volatility makes a further squeeze toward 59-61 plausible before earnings. Invalidation: a close above 61.59 (Oct 14 close) or a strong pre-earnings catalyst. Market cap 3.55B and about 64.2M shares at the 55.25 quote (stockanalysis.com); 20-day average dollar volume about 597.3M computed from daily data. Percent change for Oct 19 is from the same history page.
   Return: 6.35%; alpha: -6.48%.
3. IRON down — confidence 48%. Source session Oct 19: IRON +38.86% to close 78.93 (8.46M shares vs about 0.6M typical) after positive Phase 3 APOLLO results for bitopertin in EPP/XLP (met all primary and secondary endpoints; 41.4% placebo-adjusted PPIX reduction; resubmission planned by year-end, FDA decision expected mid-2027; per Invezz and Barron's headline). After the close the company announced a proposed $350M public offering of common stock and pre-funded warrants (GlobeNewswire/TheFly; pricing not verified). Hypothesis: reversal, direction down. Catalyst assessment: the trial result is a substantive de-risking fact; however, the stock has re-rated about +38% against a still-loss-making company (Q2 net loss 59.5M) and the offering adds supply; the inference is that follow-through is limited by dilution and regulatory timing. Several analyst target raises on Oct 20 (Truist 115, Cantor 170, Wells Fargo 124, Morgan Stanley 92) are verified via TheFly headlines on stockanalysis.com. Latest quote: latest_price 78.67 USD, quote_time 2026-10-20T10:05:00-04:00 (2026-10-20T14:05:00Z), source https://stockanalysis.com/stocks/iron/history/, delayed/near-real-time regular-session quote. (1) Pre-event price: 56.84 on 2026-10-16 close. (2) Observed event-to-quote move: +38.4% (78.67/56.84-1), nearly all of it already in the price. (3) Expected after the quote: modest giveback as the offering prices and some holders take profits; the stock has shown resilience (-0.33% after the offering news). PARTIAL SESSION as of 10:05 EDT: open 79.21, high_so_far 79.21, low_so_far 74.52, cumulative_volume 260,782 (looks low and may be a lagging print); relative intraday volume cannot be established. Price action: Oct 19 opened 72.70, ranged 69.98-80.22 and closed near the top (78.93); the 20-day high is 80.22. Counter-evidence: strong price hold after the offering announcement, a close in the upper part of the range, cash of 717.7M at June 30 and four analyst target raises. Invalidation: pricing of the offering above the market, or a sustained move above 80.22 on rising volume. Market cap 3.03B and about 38.4M shares; 20-day average dollar volume about 70.8M computed from daily closes and volumes (the 20-day average includes the 8.46M-share surge day; excluding it would be roughly 39M).
   Return: 1.69%; alpha: -1.82%.
4. SE up — confidence 42%. Source session Oct 19: SE -5.65% to close 88.47 (7.57M shares vs 4.07M 20-day average) after -3.83% on Oct 16. Hypothesis: reversal, direction up. Catalyst assessment: no company-specific news for Oct 19 was verified; the recent verified negatives are a DBS downgrade to Hold on margin concerns with a 105 target (Oct 1-2), and a TipRanks piece about cloud and Monee IPO expansion dated Oct 20. The drop appears to be sentiment/momentum rather than a change in fundamentals; that is inference. Fundamentals: Q2 revenue +48% year over year and guidance for over 1B adjusted EBITDA (Reuters/TipRanks summaries); next earnings are estimated Nov 10. Latest quote: latest_price 86.36 USD, quote_time 2026-10-20T09:16:00-04:00 (2026-10-20T13:16:00Z), source https://stockanalysis.com/stocks/se/, extended-hours (pre-market) quote, delayed, about 1 hour before the window start; a 07:07 EDT pre-market print was 88.50. No verified pre-event price, so event-to-quote move is null. The stock is already -2.4% pre-market, so the bounce thesis rests on oversold conditions and valuation (forward P/E 20.79, consensus target 154.93), which is an inference and not a catalyst. Today's regular-session open, high, low and volume were not available (PARTIAL SESSION data: none). Price action: Oct 19 opened 93.00 and closed 88.47 near the 87.88 low; this is the lowest 20-day low and close, a break below the prior 20-day range (low 87.88, high 105.39); the 5-day return is -7.7%. Counter-evidence: persistent downtrend (from 123 in late August), a breakdown to a new multi-month low on elevated volume and further pre-market weakness. Invalidation: a close below 87.88 (Oct 19 low) or a new downgrade/negative sector news. Market cap 54.19B; 20-day average dollar volume about 389.5M computed from daily data.
   Return: -4.11%; alpha: -4.24%.
5. QXO up — confidence 40%. Source session Oct 19: QXO -6.63% to close 10.14 (21.7M shares vs 24.0M 20-day average), at a new 52-week low (10.04 intraday low). Hypothesis: reversal, direction up. Catalyst assessment: no company-specific Oct 19 news was verified. The verified backdrop is a series of target cuts (Truist to 15, RBC to 18, Wells Fargo to 16 then 15) that reflect weaker channel checks and expectations, and the next earnings are estimated Nov 5. This is a drift/sentiment decline with negative estimate revisions; that is inference. Latest quote: latest_price 10.38 USD, quote_time 2026-10-20T09:54:00-04:00 (2026-10-20T13:54:00Z), source https://stockanalysis.com/stocks/qxo/, delayed/near-real-time regular-session quote (+2.37% vs 10.14). No verified pre-event price, so event-to-quote move is null. PARTIAL SESSION as of 09:54 EDT: open 10.05, day range 10.04-10.23 (as listed), cumulative_volume 1,815,831; relative intraday volume cannot be established. Price action: Oct 19 opened 10.95 and closed 10.14 near the 10.04 low; the 5-day return is -4.7%; volatility is high (daily swings of 6-8% in recent sessions). Counter-evidence: persistent lower highs and repeated new lows, falling analyst targets and strong volume on down days, which supports continuation down rather than a bounce. Invalidation: a close below 10.04 (Oct 19 52-week low) on increased volume. Market cap 10.77B reported at the quote (stockanalysis.com; 1.04B shares), and about 10.5B at the 10.14 close; 20-day average dollar volume about 275.8M computed from daily data.
   Return: -1.39%; alpha: -1.51%.

Full prediction and audit record

GPT-6

View full picks and reasoning

The October 19, 2026 source session produced unusually large, news-driven gains in biotechnology and steel alongside sharp declines in selected healthcare and critical-minerals stocks. I favor continuation where new clinical evidence changes the probability of regulatory success, but favor a reversal of Cleveland-Cliffs' earnings-driven surge because its initial October 20 reaction is already negative. ALM and IBRX are lower-confidence calls because their moves are more closely associated with analyst sentiment and positioning than newly verified operating results. The five selections meet the $5 price, $1 billion market-capitalization and $20 million 20-session average daily dollar-volume screens using the source-session close and completed-session trading history. Ranking reflects expected directional reliability, not the magnitude of the previous day's percentage move. All latest quotes are October 20 intraday observations and are separate from the five completed sessions ending October 19. The authoritative scored window runs from 2026-10-20T14:07:33.360Z to 2026-10-21T14:07:00.000Z. No future outcome is known. After the window ends, the primary score is the arithmetic mean of signed returns, using end/start minus one for up selections and its negative for down selections; directional accuracy is the fraction whose predicted sign is correct. Neither is an absolute-value return or benchmark alpha. The reported historical dollar-volume screen uses the arithmetic mean of completed-session Close multiplied by share volume; the separate avg_volume_20d field reports shares, not dollars.

1. IRON up — confidence 67%. Rank 1 because Disc Medicine's 38.86% October 19 gain followed substantive pivotal Phase 3 APOLLO results, rather than an unverified promotional claim. The company reported that bitopertin met all primary and secondary endpoints, materially improving the prospective regulatory case, although approval remains uncertain. Source: https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-success-all-primary-and-secondary . Before this catalyst, the last four completed closes were approximately $55.74-$56.84 after a broader decline. The October 19 opening gap to $72.70 from $56.84, $80.22 high and $78.93 close constituted a dramatic observed repricing, accompanied by 8,462,627 shares versus a 20-session average of 1,024,064.75 shares. The close was near the upper end of the completed session's range and the $80.22 high established a new 20-session high. That supports continuation, although the magnitude and unusually high volume also create exhaustion risk. The strongest counter-evidence is the $350 million proposed equity and warrant financing announced after the October 19 close, which introduces dilution and potential selling pressure: https://www.globenewswire.com/news-release/2026/10/19/3383860/0/en/disc-medicine-announces-proposed-350-million-public-offering-of-common-stock-and-pre-funded-warrants.html . Latest_price=79.89 USD; quote_time=2026-10-20T10:27:00-04:00; quote source=https://stockanalysis.com/stocks/iron/; quote classification=reported real-time regular-session price, with exchange-feed latency not independently verified. This is an October 20 intraday quote, not yesterday's close, and its age is measured from the stated timestamp. The observed change from the verified October 16 pre-announcement regular close of $56.84, dated 2026-10-16T16:00:00-04:00, to this quote is +40.55%; that is a cumulative repricing proxy, not a clean causal estimate of the trial announcement alone. The quote is 1.22% above the October 19 close, meaning much of the clinical news has already been reflected. PARTIAL SESSION October 20: verified open=$79.21; comparable contemporaneous high, low and cumulative volume could not be reconciled across asynchronously refreshed fields, so they are omitted. No same-time-of-day volume baseline was verified. The expected remaining-window move is further appreciation as analysts reassess approval probability, not another 38.86% gain. An elapsed-window return from the exact authoritative 10:07:33.360 EDT start cannot be isolated without a verified start-time trade. A future sustained break below October 19's $69.98 low, or financing terms that substantially undermine the reassessment, would invalidate the bullish thesis.
   Return: 1.69%; alpha: 1.56%.
2. MANE up — confidence 63%. Rank 2 because Veradermics' 12.37% October 19 gain was supported by positive Phase 3 trial results for its oral hair-loss treatment VDPHL01. The company reported statistically significant efficacy across the relevant study endpoints; Reuters independently described increased hair growth in men with pattern hair loss. This is potentially material to drug-development expectations, although regulatory approval, safety characterization and commercialization remain future uncertainties. Sources: https://www.reuters.com/business/healthcare-pharmaceuticals/veradermics-oral-hair-loss-drug-shown-boost-hair-growth-late-stage-study-2026-10-19/ and https://stockanalysis.com/stocks/mane/ . Before the announcement, completed-session closes had fallen from $116.26 on October 13 to $108.82 on October 16. On October 19, the stock gapped up to $115.34, traded between $113.00 and $123.93 and closed at $122.28, in the upper portion of its range. Volume of 1,462,574 shares exceeded its 20-session average of 900,911.95 shares. These features support catalyst continuation rather than a mechanical assumption that every large rise persists. The important counter-evidence is the October 8 20-session high of $136.72: the October 19 rally has not cleared that earlier peak, and profit-taking could resume after a widely anticipated readout. Latest_price=122.49 USD; quote_time=2026-10-20T10:22:00-04:00; quote source=https://stockanalysis.com/stocks/mane/; quote classification=reported real-time regular-session price, with feed latency not independently verified. The quote is dated October 20 and is 0.17% above the previous close. The verified October 16 regular close of $108.82 at approximately 2026-10-16T16:00:00-04:00 serves as a pre-announcement closing reference; the cumulative move to the latest quote is +12.56%, not a pure isolated study-event return. PARTIAL SESSION October 20 as of the cited snapshot: open=$120.62, high_so_far=$123.58, low_so_far=$113.52, cumulative_volume=268296 shares. These are unfinished-session observations and were excluded from the completed 20-session statistics. Without matched time-of-day volume history, relative intraday volume is unverified. Much of the positive trial news has already been priced through the Monday gap and rally; the remaining-window upside hypothesis rests on sustained institutional reassessment, not on an assumed second catalyst. The exact elapsed move since the 10:07:33.360 EDT window start is unknown because no matching start-time quote was verified. A future break below the October 19 low of $113.00 would undermine the continuation thesis.
   Return: 10.83%; alpha: 10.70%.
3. CLF down — confidence 66%. Rank 3 because Cleveland-Cliffs' October 19 gain of 16.34%, one of the session's leading gains among liquid common stocks, reacted to genuinely strong earnings and guidance but showed signs of an opening-gap fade. The verified fundamental news is substantial: management projected more than $4 billion in 2027 adjusted EBITDA versus approximately $2.54 billion in analyst consensus, alongside better-than-expected third-quarter results. Source: https://www.investopedia.com/market-update-cleveland-cliffs-stock-jumps-on-rosy-outlook-clf-12181668 . Before that report, CLF had weakened through several sessions and closed October 16 at $12.12. The October 19 event drove an opening gap to $14.20 and an intraday high of $14.58, but the stock closed at $14.10, below its opening price. Its 88,154,628-share volume was more than four times its 20-session average of 21,447,625.6 shares. Such activity confirms major repricing but can also accompany short-term exhaustion. The stock established a new 20-session high, so the breakdown thesis is not based on an absence of bullish evidence. Latest_price=13.50 USD; quote_time=2026-10-20T10:29:00-04:00; quote source=https://stockanalysis.com/stocks/clf/; quote classification=reported real-time regular-session price, feed latency unverified. This October 20 snapshot is already 4.26% below the October 19 close of $14.10. That decline is observed evidence, not an additional future profit opportunity. The verified October 16 pre-earnings regular close of $12.12 at approximately 2026-10-16T16:00:00-04:00 gives a cumulative pre-event-close-to-current gain of 11.39%; consequently, some genuine business improvement remains priced in despite the intraday fade. PARTIAL SESSION October 20 at the quoted snapshot: open=$13.68, high_so_far=$13.72, low_so_far=$12.63, cumulative_volume=13238260 shares. These values are not included in daily_5d or 20-session averages, and no same-time-of-day comparison volume was verified. I expect further moderation after the current quote over the remaining authoritative window, rather than extrapolating the decline already observed. The actual elapsed-window return since 10:07:33.360 EDT could not be separately measured. The strongest counterargument is that guidance represents a major fundamental upgrade and may attract renewed buyers. A future recovery above the verified October 19 high of $14.58 would invalidate my short-horizon reversal thesis.
   Return: 4.80%; alpha: -4.93%.
4. ALM up — confidence 53%. Rank 4 is a low-confidence upward reversal call after Almonty Industries fell 10.17% on October 19, ranking among that session's largest reported losers. The observed negative catalyst was analyst reassessment: Oppenheimer reduced its price target from $25 to $19, while maintaining an Outperform rating, and investors were evaluating the company's October 19 investor-day disclosures. Sources: https://www.insidermonkey.com/news/stock-market-movers-10-biggest-gainers-and-losers-19-october-2026-1857066/3/ and https://almonty.com/almonty-to-host-investor-day-october-19-2026/ . The analyst action is a verified valuation judgment, not newly verified evidence of an equivalent deterioration in operating performance. Before the selloff, completed-session closes had already declined from $10.98 on October 13 to $9.83 on October 16. On October 19 the stock opened at its $10.05 high, reached $8.66 and closed at $8.83, near the day's low and at the bottom of its completed 20-session price range. Volume was 12,164,001 shares against a 20-session average of 6,613,777.9. This history strongly favors downside continuation; an oversold condition by itself does not justify predicting a bounce. My opposing, lower-confidence call relies instead on the verified October 20 rebound and the possibility that the valuation response to analyst commentary was excessive. Latest_price=9.27 USD; quote_time=2026-10-20T10:27:00-04:00; quote source=https://stockanalysis.com/stocks/alm/market-cap/; quote classification=reported real-time regular-session price with latency unverified. The October 20 quote is already 4.98% above the October 19 close, so that recovery cannot be counted as future upside. PARTIAL SESSION October 20: verified open=$8.57; a consistent high, low and cumulative-volume snapshot contemporaneous with the $9.27 quote was not independently reconciled, so those values are omitted. No same-time-of-day relative-volume baseline was available. A distinct pre-analyst-action reference trade and an isolated analyst-event-to-quote reaction were not verified; both are null rather than estimated. The original October 19 gap and decline may already reflect substantial target-cut pessimism, but renewed negative analyst commentary remains a material risk. The forecast is for a further rebound after the current quote during the remaining window. The exact move since the authoritative 10:07:33.360 EDT start cannot be computed from an unavailable matching start quote. A future sustained break below the verified $8.66 October 19 low would invalidate the reversal hypothesis.
   Return: 7.10%; alpha: 6.97%.
5. IBRX down — confidence 55%. Rank 5 because ImmunityBio fell 8.28% on October 19 after a previous sharp decline, producing a sequence of deteriorating completed-session price action. The contemporaneous October 19 mover report attributed the selling to profit-taking after the stock's earlier recovery toward $10, rather than a newly established negative clinical result. Source: https://www.insidermonkey.com/news/stock-market-movers-10-biggest-gainers-and-losers-19-october-2026-1857066/3/ . Before the latest fall, IBRX closed at $9.80 on October 13, $9.91 on October 14 and $10.00 on October 15, then dropped to $9.18 on October 16. On October 19 it opened at $9.19, briefly reached $9.70, sold off to $8.31 and closed at $8.42, close to the low. The upper wick and poor close suggest unsuccessful buying during that session. Its 19,415,292 completed-session shares were only moderately above the 20-session average of 16,380,258; volume does not independently establish a capitulation or a fundamental selloff. The 20-session low of $8.26 has not yet been decisively broken, which is the principal nearby support and a reason for lower confidence. Latest_price=8.61 USD; quote_time=2026-10-20T10:26:00-04:00; quote source=https://stockanalysis.com/stocks/ibrx/market-cap/; quote classification=reported real-time regular-session price, with unverified provider latency. This October 20 quote represents a 2.26% rebound from the October 19 close, a realized move that conflicts with immediate downside continuation. PARTIAL SESSION October 20: verified open=$8.31; an internally consistent contemporaneous high, low and cumulative-volume snapshot could not be established, so they are omitted. Relative intraday volume cannot be assessed without a same-time-of-day baseline. No discrete negative October 19 operating catalyst or pre-catalyst quote was verified; therefore pre_event_price=null and event_to_quote_percent=null. The observed weakness appears principally positioning-driven, not a confirmed adverse clinical development. The remaining-window down forecast requires sellers to reassert control after the present rebound; no portion of the already observed October 19 decline is treated as future return. A trade at the authoritative 10:07:33.360 EDT window start was not verified, so the elapsed-window return is unknown. The strongest contrary evidence is the stock's recent favorable clinical-development narrative and today's rebound. A future sustained recovery above the verified October 16 closing level of $9.18 would materially weaken the continuation thesis.
   Return: -0.23%; alpha: 0.11%.

Full prediction and audit record

Muse Spark 1.1

View full picks and reasoning

October 19 rebound led by AI storage and mega-cap, but futures on Oct 20 morning turned bearish on tech earnings risk and oil spike. Premarket Oct 20 shows earnings-driven divergence: defense and aerospace beating and raising, consumer discretionary raising on gaming strength, autos mixed on trimmed EPS guidance. Setup favors continuation of strong earnings reactions and fade of weak guidance.

1. WDC up — confidence 70%. WDC was top S&P 500 gainer Oct 19 +6.09% to $352.21 close, verified by MarketBeat and StockScan. Catalyst is substantive: AI storage demand, WDC leading gainers list. Previous session close $331.87, move +5.6-6.09%. No new negative news Oct 20 premarket; stock holding bid. Continuation up expected as momentum in storage names persists. latest_price 355.635 USD quote_time 2026-10-20T07:16:00-04:00 source https://finnhub.io source type delayed quote, live=false. Prior path: Oct 16-19 decline then sharp reversal Oct 19 closing near high of day $356.2 high, indicating buying pressure. Counter-evidence: extended 5-day return already +6% and 20-day high near 382, could be overbought. Invalidation: break below Oct 19 low $341.1 on heavy volume would undermine continuation.
   Return: 4.41%; alpha: 4.29%.
2. NOC up — confidence 65%. NOC fell -1.73% Oct 19 to $510.65 close per MarketBeat and StockAnalysis, then Q3 earnings Oct 20 before open beat: $7.89 vs $7.22 estimate, revenue $11.12B +6.7% YoY, backlog $109.6B per Zacks. Substantive catalyst raising business expectations. Previous_change_percent negative so direction up is reversal. latest_price 544.19 USD quote_time 2026-10-20T07:31:00-04:00 source https://finnhub.io premarket quote +6.56% vs prior close. Prior path: down from $519 Oct 16 to $510 Oct 19, closing near low. Reversal supported by volume expansion on earnings. Counter-evidence: defense sector mixed and broader market bearish. Invalidation: failure to hold above $510.65 prior close after open would undermine reversal.
   Return: -0.77%; alpha: -0.89%.
3. RTX up — confidence 60%. RTX up modestly Oct 19 but Q3 Oct 20 before open beat strongly: revenue $24.97B vs $24.16B est, +11.1% YoY, raised FY EPS to $7.65-7.75 from $7.10-7.25 per Reuters via TradersUnion, and sales to $97-97.5B from $95-96B. Substantive raise, third raise this year. Previous_change_percent was +0.8% estimated, so continuation up. latest_price 196.01 USD quote_time 2026-10-20T08:30:00-04:00 source https://premarketprice.com/premarket-movers +2.03% premarket. Prior path Oct 19 flat to up small, closing near middle of range, volume normal. Continuation likely as backlog record supports further. Counter-evidence: aerospace already priced for recovery, market risk-off. Invalidation: close below Oct 19 low ~ $190 would negate.
   Return: -2.01%; alpha: -2.14%.
4. HAS up — confidence 62%. HAS top premarket gainer Oct 20 +4.84% to $103.26 per premarketprice.com, after Q3 results Oct 20 before open: revenue +15%, Wizards and Digital Gaming +31%, Magic over $600M, raised FY constant-currency growth to 7-9% from 5-7% per TradingView dpa-AFX and doubled buyback target. Substantive catalyst. Previous_change_percent Oct 19 was +1.2% (small up), so continuation up. latest_price 103.26 USD quote_time 2026-10-20T08:00:00-04:00 source https://premarketprice.com/premarket-movers delayed. Prior path: HAS rising into earnings, close Oct 19 around $98.49, volume 2.41M 9.8x. Counter-evidence: consumer products only +4% and entertainment still small, gaming concentration risk. Invalidation: close below $98.49 prior close would break thesis.
   Return: 8.08%; alpha: 7.95%.
5. GM down — confidence 65%. GM fell -1.62% Oct 19 to $82.60 close per MarketBeat, then Q3 Oct 20 before open: revenue $50.0B vs $48.52B est, EPS $3.70 vs $3.57 beat per Yahoo, but narrowed FY adjusted EBIT to $14.5-15.5B from $14-16B and trimmed EPS to $12.75-13.75, plus $20B buyback announced. Market reaction negative premarket -6.98% at $76.97 per Sharecast, indicating guidance trim outweighs beat. Substantive mixed catalyst leaning negative. Previous_change_percent negative, so continuation down. latest_price 78.425 USD quote_time 2026-10-20T07:30:00-04:00 source https://finnhub.io current down -5.22%. Prior path: GM down 5-day -5.2%, closing near low, volume high 7.9M. Counter-evidence: buyback and auto free cash flow raised could support. Invalidation: if GM reclaims $82.75 prior close on high volume, down thesis fails.
   Return: -2.86%; alpha: 2.73%.

Full prediction and audit record

Perplexity

View full picks and reasoning

The last completed U.S. session (2026-10-19) showed a selective technology rebound after a difficult AI-hardware week, while several high-multiple software and power names remained under analyst pressure. I favor continuation in the strongest earnings/upgrade-driven gainers and continuation lower in names facing concrete downgrade or target-cut catalysts, while recognizing that one-day momentum is unstable and the current session had already shown mixed early action.

1. WDC up — confidence 55%. Western Digital gained 6.09% in the completed 2026-10-19 session as chip and storage stocks rebounded; the source-session move is positive, so continuation requires direction up. The catalyst is partly substantive: analysts argued the recent HDD selloff was overdone, but the immediate move also reflects sentiment around the AI-storage trade rather than a new operating result. Latest verified quote is 346.40 USD at 2026-10-20T09:41:00-04:00, a live regular-session quote, down 1.65% from the prior close; the stock was already giving back part of Monday's gain, so the remaining-window continuation call is lower confidence. Price action supports caution: the latest quote is below the 2026-10-19 close of 352.21 and the day's early range was 342.50-352.77. Strongest counter-evidence is the early-session fade plus recent Wells Fargo, UBS, and Morgan Stanley price-target reductions. Invalidation: a sustained move below the verified 2026-10-20 intraday low of 342.50 would undermine the continuation thesis. I could not verify the full five-day OHLC series, 20-day high/low, average dollar volume, or 20-day average share volume from the available sources, so those fields are null. Source descriptions: StockAnalysis provided the live quote, market cap, and recent news; Yahoo Finance/MarketWatch reporting described the 2026-10-19 storage-stock rebound.
   Return: 4.41%; alpha: 4.29%.
2. DDOG up — confidence 60%. Datadog rose 5.36% in the completed 2026-10-19 session, so continuation requires direction up. The catalyst is substantive relative to a pure sentiment move: Bernstein upgraded DDOG to Outperform and raised its target to 350 USD from 237 USD, citing data suggesting stronger-than-expected enterprise token consumption. The latest verified quote is 261.00 USD at 2026-10-19T18:12:00-04:00, an after-hours quote, up 0.25% from the 261.00 regular-session close; it is stale relative to the current session, so confidence is tempered. The completed session closed at 261.00 versus a 266.00 high, indicating some late-session fade, but the close remained near the upper part of the 256.14-266.00 range. Strongest counter-evidence is the elevated valuation and the fact that the upgrade-driven gain may already be largely priced in. Invalidation: a sustained move below the verified 2026-10-19 low of 256.14 would undermine the continuation thesis. Market cap and latest available quote were verified; the full five-day history, 20-day range, and 20-day volume averages could not be verified and are null. Source descriptions: StockAnalysis supplied quote, OHLC, market cap, and upgrade news; Yahoo Finance reporting identified DDOG as a top gainer after the Bernstein upgrade.
   Return: 5.05%; alpha: 4.93%.
3. TWLO up — confidence 55%. Twilio rose 5.29% in the completed 2026-10-19 session, so continuation requires direction up. The catalyst combines a substantive index event with analyst sentiment: Twilio's previously announced S&P 500 inclusion and a BTIG target increase to 315 USD from 285 USD supported the move; these are verifiable catalysts, though the index effect is largely mechanical and the AI-agent enthusiasm is more speculative. Latest verified quote is 258.00 USD at 2026-10-19T19:30:00-04:00, an after-hours quote, up 0.28% from the 258.00 close; it is stale. The completed session closed at 258.00 versus a 259.79 high, leaving limited upper wick and a relatively strong close. Strongest counter-evidence is valuation and the recent HSBC Reduce rating, which highlights the risk that the rally extends an already large 12-month advance. Invalidation: a sustained move below the verified 2026-10-19 low of 248.00 would undermine the continuation thesis. The full five-day series, 20-day range, and 20-day volume averages were not verifiable from available sources and are null. Source descriptions: StockAnalysis provided quote, OHLC, market cap, and analyst-news context; Yahoo Finance reporting listed TWLO among the session's top gainers after the BTIG action.
   Return: 4.75%; alpha: 4.63%.
4. NRG down — confidence 55%. NRG Energy fell 4.21% in the completed 2026-10-19 session, so continuation requires direction down. The catalyst is substantive: Jefferies cut its target to 131 USD from 160 USD and Seaport cut its target to 160 USD from 190 USD, reflecting reduced near-term valuation expectations even though both maintained Buy ratings. The latest verified quote is 99.34 USD at 2026-10-19T19:53:00-04:00, an after-hours quote, essentially flat versus the 99.34 close; it is stale. The completed session opened at 104.71, traded as high as 105.71, and closed at 99.34 near the 97.61 low, a bearish close near the bottom of the range. Strongest counter-evidence is that the dividend announcement and a newly initiated CIBC Outperformer rating provide some positive offsets, and the stock is near its 52-week low of 93.36, where oversold bounces can occur. Invalidation: a sustained move above the verified 2026-10-19 open of 104.71 would undermine the down/continuation thesis. The full five-day series, 20-day range, and 20-day volume averages were not verifiable and are null. Source descriptions: StockAnalysis supplied quote, OHLC, market cap, and target-cut news; Yahoo Finance reporting identified NRG as a top loser after multiple broker target cuts.
   Return: -0.32%; alpha: 0.20%.
5. AMP down — confidence 55%. Ameriprise fell 4.07% in the completed 2026-10-19 session, so continuation requires direction down. The catalyst is substantive: BofA downgraded AMP to Underperform from Buy and cut its target to 445 USD from 570 USD, citing advisor attrition and retention-cost pressure. The latest price I could verify is 481.68 USD at 2026-10-19T09:52:00-04:00, a prior-session regular-hours intraday quote rather than a current quote; its freshness is limited, so confidence is reduced. The verified intraday range that morning was 484.66-495.00 with an open of 487.79, and the reported 4.07% source-session decline indicates the stock closed materially lower, but I could not verify the exact session close, five-day OHLC, 20-day range, or 20-day volume averages; those fields are null. Strongest counter-evidence is the company's recent announcement that three advisor teams with nearly 1.2 billion USD in combined assets joined from RBC, plus an additional 5.5 billion USD buyback authorization. Invalidation: a sustained move above the verified 2026-10-19 intraday high of 495.00 would undermine the down/continuation thesis. Source descriptions: StockAnalysis provided the quote, market cap, intraday range, and downgrade news; Yahoo Finance reporting identified AMP as a top loser after the BofA downgrade.
   Return: 0.51%; alpha: -0.63%.

Full prediction and audit record

Gemini 3 Pro

View full picks and reasoning

US stock markets reflect sector dispersion driven by Q3 earnings reports and company-specific catalysts, alongside persistent volatility in AI infrastructure and high-leverage technology names.

1. IRON up — confidence 75%. Disc Medicine surged 38.86% in the source session following positive Phase 3 bitopertin trial endpoint data, with Cantor Fitzgerald raising its price target to $170 and Truist to $115. Latest price: $78.93 USD as of 2026-10-20T13:45:00Z (delayed pre-market quote from https://ca.investing.com/news/stock-market-news/cantor-fitzgerald-raises-disc-medicine-stock-price-target-on-trial-data-93CH-4890688). Prior to the event, IRON traded around $56.84; the observed event reaction was a 38.86% surge to $78.93 on 10x normal volume. Over the remaining forecast window, momentum is expected to continue upward. Counter-evidence includes potential short-term profit-taking after a massive single-day gain. Invalidation level: a intraday fall below $69.98.
   Return: 1.69%; alpha: 1.56%.
2. CLF up — confidence 70%. Cleveland-Cliffs reported Q3 adjusted EBITDA of $612M (beating $575M guidance) and doubled its FY27 outlook, driving a 16.34% gain in the source session. Latest price: $14.13 USD as of 2026-10-20T13:30:00Z (delayed pre-market quote from https://www.trefis.com/data/companies/CLF). Pre-event price was $12.14; observed reaction was +16.34% to $14.13. Further upside is expected following Goldman Sachs target upgrade to $13. Counter-evidence includes steel sector macro cyclicality. Invalidation level: breach below $12.50.
   Return: 4.80%; alpha: 4.67%.
3. CRWV down — confidence 65%. CoreWeave declined 11.91% in the source session due to high debt load fears and bond yield spikes, extending a 25% weekly selloff. Latest price: $63.08 USD as of 2026-10-20T13:00:00Z (delayed pre-market quote from https://www.tradingnews.com/news/coreweave-63-usd-trades-as-an-option-on-its-credit-a-112-percent-revenue-growth-meets). Pre-event price was $69.70; observed event reaction was -11.91% to $61.39 before ticking up to $63.08. Heavy selling pressure is expected to continue due to ongoing credit spread expansion. Counter-evidence includes strong +112% revenue growth attracting value buyers. Invalidation level: breach below $59.25.
   Return: 3.38%; alpha: -3.51%.
4. INTC up — confidence 65%. Intel gained 2.43% in the source session, bouncing off key support near $89.19 with over 101M shares traded. Latest price: $92.03 USD as of 2026-10-20T13:15:00Z (delayed pre-market quote from https://www.investing.com/equities/intel-corp-historical-data). Pre-event price was $89.85; observed reaction was +2.43% to $92.03. Technical stabilization and high volume support continued upside over the target session. Counter-evidence includes semiconductor industry sentiment fragility. Invalidation level: breakdown below $89.19.
   Return: 0.26%; alpha: 0.14%.
5. CIEN up — confidence 60%. Ciena lost 2.05% in the source session, extending an 8% 5-day drop in optical telecom stocks. Latest price: $337.15 USD as of 2026-10-20T13:10:00Z (delayed pre-market quote from https://www.chartmill.com/stock/quote/CIEN/profile). Pre-event price was $344.20; observed reaction was -2.05% to $337.15. Oversold technical indicators near $335 combined with bullish analyst price targets (Evercore ISI at $550) favor a mean-reversion reversal upward. Counter-evidence includes risk of extended capex delays across telecom customers. Invalidation level: breach below $335.00.
   Return: 3.39%; alpha: 3.27%.

Full prediction and audit record

DeepSeek

View full picks and reasoning

US equities are mixed in Tuesday morning trading after Monday's AI and memory-chip rebound. CLF is giving back a large earnings-driven gain, while WDC, SNDK, AMZN and TSLA are holding or extending Monday's advances. The dominant theme is a sentiment-led tech bounce rather than a broad fundamental re-rating, so continuation calls are made with modest confidence.

1. CLF down — confidence 72%. CLF is the top down-reversal pick: it closed the Oct 19 source session +16.34% at $14.10 after Q3 earnings beat, a Q4 EBITDA guide of about $715M and 2027 EBITDA guidance above $4B, and Bloomberg reported an intraday gain of as much as 20%. The latest live regular-session quote is $13.42 at 2026-10-20T10:24:17-04:00 from Yahoo Finance, down 4.82% from that close, so the direction is down against a positive source-session move (reversal). The catalyst was substantive, but the rapid give-back and 88.4M-share source-session volume indicate profit-taking; the 20-day high of $14.58 and the 5-day +9.39% move show the stock had become extended. Counter-evidence is that strong guidance and tariff-supported steel prices could attract dip buyers. Invalidation is a close back above $14.10.
   Return: 4.80%; alpha: -4.93%.
2. AMZN up — confidence 66%. AMZN closed the Oct 19 source session +4.98% at $262.45 after Morgan Stanley named it a top pick and mega-cap technology rebounded. The catalyst is primarily a sell-side recommendation and sector sentiment, not a change in near-term business expectations. The latest live regular-session quote is $264.24 at 2026-10-20T10:29:50-04:00 from Yahoo Finance, up 0.68% from that close, so direction is up and the hypothesis is continuation. Source-session volume of 56.1M was above the 20-day average of 36.5M, supporting the move, and the stock is above its 20-day high of $263.72. Counter-evidence is that mega-cap gains can fade quickly if the AI rebound stalls. Invalidation is a break below $262.45.
   Return: -1.15%; alpha: -1.28%.
3. WDC up — confidence 64%. WDC closed the Oct 19 source session +6.09% at $352.21 as memory and AI-linked chip stocks rebounded after the Philadelphia Semiconductor Index's eight-session slide. The catalyst was sector-wide and substantive for sentiment but not a company-specific estimate change. The latest live regular-session quote is $358.73 at 2026-10-20T10:30:04-04:00 from Yahoo Finance, up 1.85% from that close, so direction is up and the hypothesis is continuation. WDC opened lower at $349.50, dipped to $342.59 and then recovered above the prior close, showing buyers defended the move; source-session volume of 7.8M was close to the 20-day average of 9.0M. Counter-evidence is the wide intraday range and premarket weakness, which show the rally is fragile. Invalidation is a break below $352.21.
   Return: 4.41%; alpha: 4.29%.
4. TSLA up — confidence 60%. TSLA closed the Oct 19 source session +3.76% at $368.06 in the broad technology and AI rebound. No company-specific catalyst was verified beyond the sector move, so the catalyst is largely sentiment-driven. The latest partial-session quote is $374.79 on Oct 20 from the Yahoo Finance history row, up 1.83% from the source close, so direction is up and the hypothesis is continuation. The timestamp of that quote is unavailable, and freshness cannot be verified; it should be treated as an intraday regular-session observation. Source-session volume of 38.7M was slightly above the 20-day average of 34.6M, and the stock closed near the upper end of Monday's range. Counter-evidence is that without a fundamental catalyst, a broad market reversal could quickly drag TSLA back. Invalidation is a break below $368.06.
   Return: 3.62%; alpha: 3.50%.
5. SNDK up — confidence 58%. SNDK closed the Oct 19 source session +5.53% at $1,371.12 in the memory-chip rebound after the sector's sharp selloff. The catalyst is sector sentiment and valuation recovery rather than company-specific news. The latest live regular-session quote is $1,382.36 at 2026-10-20T10:29:23-04:00 from Yahoo Finance, up 0.82% from that close, so direction is up and the hypothesis is continuation. It opened lower at $1,336.96 and rallied, but it remains below its $1,407.00 intraday high and far below the 20-day high of $1,909.48. Counter-evidence is that the fade from the high and SNDK's high valuation could produce exhaustion. Invalidation is a break below $1,357.64.
   Return: -0.85%; alpha: -0.98%.

Full prediction and audit record

Grok

View full picks and reasoning

October 19 session featured extreme biotech M&A jumps (SLN, IRON) alongside steel and storage rebounds after prior tech weakness; breadth mixed with large-cap tech recovering modestly while selected growth names sold off on insider flow and guidance concerns. Near-term bias favors selective continuation in deal-driven names and high-volume rebounders, with potential mean-reversion in oversold large-caps.

1. SLN up — confidence 68%. Silence Therapeutics closed Oct 19 at 19.58 after +125.58% on Merck KGaA acquisition agreement at roughly matching cash terms; latest quote near 19.58 (delayed regular-session, source stockanalysis.com as of ~10:25 EDT Oct 20) shows the move already largely reflected with minimal residual premium. Catalyst is substantive M&A (definitive agreement filed), changing ownership and near-term valuation floor rather than pure sentiment. Price history supports continuation as the gap filled to deal value on extreme volume; counter-evidence is that cash deals often trade flat-to-slightly-down post-announcement once premium is captured. Invalidation would be a break below 18.50 on regulatory or financing noise. Avg dollar volume on the catalyst day far exceeded 20M threshold; market cap ~1.18B post-move meets floor.
   Return: 0.29%; alpha: 0.16%.
2. IRON up — confidence 62%. Disc Medicine rose 38.86% to 78.93 on Oct 19 on high volume (~8.5M shares); latest quote around 78-79 range (delayed, source marketbeat/chartexchange ~10:20 EDT Oct 20). Catalyst appears data or pipeline related supporting hematology assets; move is large but not pure M&A, so residual momentum possible. Price action shows strong close near highs after gap-up, favoring continuation. Counter-evidence is elevated short interest and prior multi-day weakness. Invalidation below prior-session low 69.98. Market cap ~3.0B and dollar volume well above floors.
   Return: 1.69%; alpha: 1.56%.
3. CLF up — confidence 58%. Cleveland-Cliffs gained 16.34% to 14.10 on Oct 19 with massive volume (~88M shares); latest quote ~13.10-13.50 (delayed open session Oct 20). Earnings-related move after prior weakness; high absolute volume confirms liquidity. Price closed near highs after gap, supporting continuation. Counter-evidence is steel sector cyclicality and today's early pullback. Invalidation below 12.12 prior close. Market cap ~8B and 20-day dollar volume far exceeds 20M.
   Return: 4.80%; alpha: 4.67%.
4. WDC up — confidence 55%. Western Digital rose 6.09% to 352.21 on Oct 19 amid memory/storage rebound after prior sell-off; latest quote ~345-350 range (delayed, ~09:55 EDT Oct 20). Sector relief and solid fundamentals (strong recent revenue/EPS growth) support further upside. Volume solid relative to average. Counter-evidence is the stock still well off 52-week highs after multi-week decline. Invalidation below 332 prior close. Market cap >120B and dollar volume comfortably above threshold.
   Return: 4.41%; alpha: 4.29%.
5. SE up — confidence 52%. Sea Limited fell 5.65% to 88.47 on Oct 19 on elevated volume amid insider selling and continued downtrend; latest quote ~83 range (delayed Oct 20). Oversold relative to recent range and positive longer-term growth narrative (Shopee/Garena scale) support a one-day bounce (reversal). Counter-evidence is persistent insider sales and weak relative strength. Invalidation below 87.88 session low. Market cap ~50B and average dollar volume well above 20M.
   Return: -4.11%; alpha: -4.24%.

Full prediction and audit record

How models have done in Extreme Movers + OHLC

ForecastNest's own settled Extreme Movers + OHLC runs at this horizon, up to and including this one. Members' own research is not counted. Runs created after their scoring window began, or with an unverified start time, are excluded. The chart is the average directional return per run. A bar drawn pale is inside its own sample noise -- the runs behind it scatter too widely for that average to separate from zero -- so read the ordering as provisional until the record is deep enough to carry it. The table below adds how many of the five directions were called correctly, which is a steadier measure on a short record because it counts several picks a run rather than one result.

Chart note — “within noise”: The pale bar means the observed average is not clearly separated from zero by this chart's rule, or there is not enough information to assess it. A solid bar requires an average at least two standard errors from zero (standard error = sample standard deviation ÷ √runs). Fewer than two runs, missing variability, or zero measured variability remain pale. This is a rough uncertainty indicator, not proof of no effect or a guarantee of future performance.

Model	Runs	Avg directions called correctly	Avg directional return
GPT-6	6	66.67%	+1.71%
Grok	1	80.00%	+1.42%
Perplexity	6	53.33%	+1.09%
Gemini 1.5 Pro	3	71.67%	+0.96%
Muse Spark 1.1	6	53.33%	-0.23%
DeepSeek	6	43.33%	-0.53%
Grok 4.5	4	35.00%	-0.54%
Gemini 3 Pro	2	50.00%	-0.74%
Grok 4	1	40.00%	-1.54%
Claude Sonnet 5.5	1	0.00%	-3.67%

View settlement prices

Symbol	Start	End	Source	Notes
ALM	8.82860000	9.45500000	https://finance.yahoo.com/quote/ALM/history/
AMP	486.33250000	488.80000000	https://finance.yahoo.com/quote/AMP/history/
AMZN	263.03000000	260.00500000	https://finance.yahoo.com/quote/AMZN/history/
AXTI	55.04500000	58.54000000	https://finance.yahoo.com/quote/AXTI/history/
CIEN	345.50000000	357.22500000	https://finance.yahoo.com/quote/CIEN/history/
CLF	13.12500000	13.75500000	https://finance.yahoo.com/quote/CLF/history/
CRWV	59.77500000	61.79500000	https://finance.yahoo.com/quote/CRWV/history/
DDOG	256.96000000	269.94000000	https://finance.yahoo.com/quote/DDOG/history/
GM	78.28000000	76.04500000	https://finance.yahoo.com/quote/GM/history/
HAS	103.29000000	111.63500000	https://finance.yahoo.com/quote/HAS/history/
IBRX	8.60500000	8.58500000	https://finance.yahoo.com/quote/IBRX/history/
INTC	91.33000000	91.57010000	https://finance.yahoo.com/quote/INTC/history/
IRON	78.69000000	80.02000000	https://finance.yahoo.com/quote/IRON/history/
MANE	119.90000000	132.88000000	https://finance.yahoo.com/quote/MANE/history/
NOC	546.93000000	542.73000000	https://finance.yahoo.com/quote/NOC/history/
NRG	99.13000000	98.81000000	https://finance.yahoo.com/quote/NRG/history/
QXO	10.46500000	10.31990000	https://finance.yahoo.com/quote/QXO/history/
RTX	195.95500000	192.01000000	https://finance.yahoo.com/quote/RTX/history/
SE	82.40050000	79.01000000	https://finance.yahoo.com/quote/SE/history/
SLN	19.57500000	19.63160000	https://finance.yahoo.com/quote/SLN/history/
SNDK	1370.65000000	1359.00000000	https://finance.yahoo.com/quote/SNDK/history/
SPY	768.34000000	769.31000000	https://finance.yahoo.com/quote/SPY/history/
TSLA	371.77000000	385.24500000	https://finance.yahoo.com/quote/TSLA/history/
TWLO	255.48500000	267.63000000	https://finance.yahoo.com/quote/TWLO/history/
WDC	354.76000000	370.42000000	https://finance.yahoo.com/quote/WDC/history/

Standard prompt extreme-movers-v11+ohlc3, SHA-256 f476006274cdc46d02332f32b4249b1f6d34939428aa9f680d2b2d372d6c0fb5. The prompt is available to ForecastNest members; the fingerprint shows it was not changed after the fact.

Calculation: extreme-movers-ohlc-v1.